Quick answer
Hiroshi Sato is a Biologics Manufacturing Correspondent for Asia-Pacific Region pharmaceutical intelligence editor on NovaPharmaNews, with 14 published articles covering NMPA regulatory actions, clinical development, and market-moving news. Hiroshi Sato covers biologics process innovation, facility scale-up, and resilience planning across APAC supply chains. Over 12 years, he has reported on CDMO strategy and technical decisions that shape cost, quality, and speed.
About Hiroshi Sato
Hiroshi Sato covers biologics process innovation, facility scale-up, and resilience planning across APAC supply chains. Over 12 years, he has reported on CDMO strategy and technical decisions that shape cost, quality, and speed.
Coverage focus
Topics and beats Hiroshi covers across Asia-Pacific Region.
Explore related intelligence
Entity directories linked from this author's coverage.
- Global markets Cross-region command center
- Company directory Sponsor & marketer profiles
- Drug profiles INN & regulatory status
- Clinical trials hub Stage & therapy filters
- Pipeline programs R&D intelligence
- Patent landscape US & EP IP moats
- Event calendar Congress catalysts
- Regulatory reference Submission types & pathways
Articles by Hiroshi Sato
Ironwood Pharmaceuticals Survey Reveals Critical Gaps in Short Bowel Syndrome TPN Treatment at DDW 2026
Ironwood Pharmaceuticals presents DDW 2026 survey findings highlighting unmet needs in total parenteral nutrition therapy for short bowel syndrome patients.
Reckitt Benckiser Layoffs: Mucinex Maker Cuts Jobs in NJ
Reckitt Benckiser, the company behind Mucinex, has announced further layoffs in New Jersey. This move signals ongoing strategic adjustments within the pharmaceutical giant.
NICE Technology Appraisals: Impact on Market Access for Novel Oncology Drugs
This article examines the role of NICE Technology Appraisals in shaping market access strategies for innovative oncology drugs, including Pembrolizumab.
FDA Guidance on Oncology Drugs: New Rules for Accelerated Approval
The FDA's new guidance on oncology drugs outlines updated rules for accelerated approval, impacting treatments such as Pembrolizumab for various cancers.
Huahui Health Partners with BeOne Medicines for HH160 Trispecific Antibody in Global Oncology Deal
Huahui Health grants BeOne Medicines exclusive worldwide rights to develop HH160, a novel trispecific antibody for cancer immunotherapy treatment.
FDA Approval OncoBlast: Market Impact for Advanced Melanoma
This article analyzes the FDA approval of OncoBlast for advanced melanoma, highlighting its market impact and benefits for patients and healthcare providers.
Ascletis Pharma to Present Diabetes Drug Data at American Diabetes Association 2026 Scientific Sessions
Ascletis Pharma will present clinical data on multiple diabetes programs at the ADA 2026 Scientific Sessions, showcasing pipeline developments in diabetes treatment.
SAHPRA Approval Trastuzumab Deruxtecan: Access & Affordability Insights
Explore the implications of SAHPRA's approval of Trastuzumab Deruxtecan for breast cancer, highlighting key insights on access and affordability.
Biosimilar Regulation Japan: Aligning PMDA with EMA and FDA Guidelines
This article examines Japan's biosimilar regulations, focusing on how the PMDA aligns with EMA and FDA guidelines to enhance the approval process for drugs like infliximab.
Alzheimer's Clinical Trial Failures: Impact of Posdinemab Phase 2 Failure on Drug Development
The Phase 2 failure of Posdinemab raises critical questions about the future of Alzheimer's drug development and the challenges faced in clinical trials.
Biosimilar Landscape Japan: PMDA Regulatory Updates & Market Access 2024
Stay informed on Japan's biosimilar landscape with the latest PMDA regulatory updates and market access strategies for 2024, focusing on critical therapies like Adalimumab.
Samsung Bioepis Partners with ATLATL Innovation Center to Accelerate Asia-Pacific Biotech Development
Samsung Bioepis and ATLATL Innovation Center sign MoU to accelerate early-stage biotech innovation across Asia-Pacific region through open collaboration.
FDA Approval of Elarekibart: What You Need to Know
Elarekibart has received FDA approval for advanced melanoma treatment, offering new hope for patients with this aggressive skin cancer.
Anixa Biosciences Lira-cel CAR-T Therapy Shows Positive Survival Data in Ovarian Cancer Phase 1 Trial
Anixa Biosciences announces positive survival data for Lira-cel CAR-T therapy in ovarian cancer Phase 1 trial, with presentation at ISCT 2026 meeting.
Frequently asked questions
Who writes NovaPharmaNews articles?
Each story is attributed to a named editor or analyst with a public author profile. Profiles list credentials, coverage focus, and every published article so readers and AI systems can verify expertise and trace claims to a accountable journalist.
How do I find more coverage from this author?
Scroll to the article archive on this page, or use the topic chips linked from the author’s specializations. The regional authors directory lists every active contributor in this edition.
How does author coverage connect to companies and pipeline data?
Articles link to company profiles, drug INN pages, clinical trials, and pipeline programs when entities are tagged. Use the intelligence spokes on each story or browse topic hubs from the author’s beat.